Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E STEPHENSON

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
The European Respiratory Journal|July 13, 2023
Oxidised IL-33 drives COPD epithelial pathogenesis <i>via</i> ST2-independent RAGE/EGFR signalling complexSam Strickson, Kirsty F Houslay, Victor A Negri, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
Nature|June 9, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humansGalit Alter, Jingyou Yu, Jinyan Liu, et al.
Cell|November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysDan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Physical Review Letters|May 23, 2006
Polarized proton collisions at 205 GeV at RHICM Bai, T Roser, L Ahrens, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
The European Respiratory Journal|July 13, 2023
Oxidised IL-33 drives COPD epithelial pathogenesis <i>via</i> ST2-independent RAGE/EGFR signalling complexSam Strickson, Kirsty F Houslay, Victor A Negri, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
Nature|June 9, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humansGalit Alter, Jingyou Yu, Jinyan Liu, et al.
Cell|November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysDan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Physical Review Letters|May 23, 2006
Polarized proton collisions at 205 GeV at RHICM Bai, T Roser, L Ahrens, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Pageof 18